PKM and cancer: Though cancer cells exhibit a high rate of glycolysis, PKM2 has a lower catalytic activity than PKM1; this produces a bottleneck in glycolysis which allows the build-up of glycolytic intermediates that can be utilised for anabolic processes, at the expense of ATP production [14–17].